Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04921241 · ClinicalTrials.gov registry record
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 86
- Enrollment target
NCT04921241: Completed study, sponsored by Massachusetts General Hospital.
NCT04921241 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04921241 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. In this context, a new population of children has emerged who were exposed to maternal COVID-19 in the womb. As maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. In the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without COVID-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. This work stands to benefit the burgeoning population of children exposed to COVID-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections.
Interventions
- OTHER In Utero Exposure to SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2024-01-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04921241
The ClinicalTrials.gov registry entry for NCT04921241 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which In Utero Exposure to SARS-CoV-2 is the first listed.
NCT04921241 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04921241 about?
NCT04921241 is a clinical study titled "In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life". Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence...
What is the current status of trial NCT04921241?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2021-06-08. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT04921241?
The interventions under investigation include: In Utero Exposure to SARS-CoV-2 (OTHER).
Who is sponsoring clinical trial NCT04921241?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.